IRIS
DE GIORGI, UGO FEDERICO FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.654
NA - Nord America 502
SA - Sud America 482
EU - Europa 162
AF - Africa 58
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 5.860
Salva come PNG Salva come JPEG
Nazione #
HK - Hong Kong 2.186
SG - Singapore 1.743
US - Stati Uniti d'America 423
BR - Brasile 413
CN - Cina 321
VN - Vietnam 189
IN - India 59
BD - Bangladesh 48
IT - Italia 47
MX - Messico 42
GB - Regno Unito 27
AR - Argentina 25
IQ - Iraq 20
CA - Canada 19
ZA - Sudafrica 18
EC - Ecuador 14
TR - Turchia 14
DE - Germania 12
SA - Arabia Saudita 12
NL - Olanda 11
UZ - Uzbekistan 11
PL - Polonia 10
UA - Ucraina 10
CO - Colombia 9
ID - Indonesia 8
MA - Marocco 8
PK - Pakistan 8
RU - Federazione Russa 8
TN - Tunisia 8
JP - Giappone 7
CL - Cile 6
ES - Italia 6
DZ - Algeria 5
ET - Etiopia 5
FR - Francia 5
JM - Giamaica 5
KE - Kenya 5
UY - Uruguay 5
VE - Venezuela 5
EG - Egitto 4
AT - Austria 3
AZ - Azerbaigian 3
BB - Barbados 3
JO - Giordania 3
MD - Moldavia 3
NP - Nepal 3
OM - Oman 3
PS - Palestinian Territory 3
PY - Paraguay 3
SE - Svezia 3
AE - Emirati Arabi Uniti 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
FI - Finlandia 2
GH - Ghana 2
HN - Honduras 2
KG - Kirghizistan 2
LT - Lituania 2
LV - Lettonia 2
MY - Malesia 2
PH - Filippine 2
PT - Portogallo 2
AL - Albania 1
AU - Australia 1
BE - Belgio 1
BG - Bulgaria 1
CG - Congo 1
CY - Cipro 1
CZ - Repubblica Ceca 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
IE - Irlanda 1
IL - Israele 1
IR - Iran 1
KZ - Kazakistan 1
LY - Libia 1
MK - Macedonia 1
NI - Nicaragua 1
PA - Panama 1
PE - Perù 1
PR - Porto Rico 1
RO - Romania 1
RS - Serbia 1
SN - Senegal 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.860
Salva come PNG Salva come JPEG
Città #
Hong Kong 2.185
Singapore 269
San Jose 112
Beijing 55
Ho Chi Minh City 54
Hanoi 52
Ashburn 33
São Paulo 30
Mexico City 21
Los Angeles 18
Dhaka 14
Da Nang 13
Orem 13
Santa Clara 13
Mumbai 12
New York 11
Rio de Janeiro 10
Warsaw 10
San Pietro Vernotico 9
Tashkent 9
Baghdad 8
Biên Hòa 7
New Delhi 7
Thái Nguyên 7
Goiânia 6
Johannesburg 6
Milan 6
Porto Alegre 6
Salvador 6
Tokyo 6
Addis Ababa 5
Boardman 5
Brasília 5
Brooklyn 5
Chennai 5
Chicago 5
Council Bluffs 5
Guayaquil 5
Haiphong 5
Montreal 5
Nairobi 5
Riyadh 5
San Francisco 5
Santiago 5
Bologna 4
Cape Town 4
Caxias do Sul 4
Chiarano 4
Cotia 4
Dallas 4
Dammam 4
Franca 4
Juiz de Fora 4
Orlando 4
Piracicaba 4
Querétaro 4
Ribeirão Preto 4
Santo André 4
Sumaré 4
São Bernardo do Campo 4
Tunis 4
Uberlândia 4
Ankara 3
Asunción 3
Atlanta 3
Baku 3
Belo Horizonte 3
Bragança Paulista 3
Bridgetown 3
Casablanca 3
Chapecó 3
Charlotte 3
Curitiba 3
Da Lat 3
Erbil 3
Fort Lauderdale 3
Fortaleza 3
Frankfurt am Main 3
Istanbul 3
Kingston 3
Kyiv 3
Lahore 3
Limeira 3
Manaus 3
Manchester 3
Osasco 3
Phoenix 3
Pune 3
Ribeirão das Neves 3
Rio Grande 3
Stockholm 3
The Bronx 3
Trento 3
Adamantina 2
Alegrete 2
Alvorada 2
Amman 2
Amsterdam 2
Aracaju 2
Bari 2
Totale 3.257
Salva come PNG Salva come JPEG
Nome #
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 110
68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer 105
A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity 102
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. 100
Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. 85
Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey 82
Prevention and therapy of neutropenia in elderly patients 81
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer 76
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial 73
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials 60
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 60
Adjuvant concomitant chemotherapy in pancreatic cancer. 59
Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis 59
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study 58
[177 Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet? 58
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial 58
68 Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients 58
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry 57
18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases 54
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial 54
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone 53
A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: a phase II pilot study 53
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial 53
PSMA expression: A potential ally for the pathologist in prostate cancer diagnosis 52
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial 52
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry 51
Anticancer drug delivery with nanoparticles 50
A Phase II study of everolimus plus oral prednisone in patients with metastatic renal cell cancer 50
International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer 49
Conditional survival of patients treated with first-line chemotherapy for metastatic urothelial cancer 49
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 49
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients 49
A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer 49
Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer 49
A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization 48
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 47
Salvage high-dose chemotherapy in female patients with relapsed/refractory germ cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT) 46
Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features 46
Clinical pharmacology of intraperitoneal cisplatin-based chemotherapy. 43
Ovarian Sertoli-Leydig cell tumor, endometrioid-like yolk sac tumor, and Y-chromosomal material 43
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial 43
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 43
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: Results from the Italian national registry 43
[18F]fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapy. 41
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial 41
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. 41
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 41
Long-term follow-up of patients with poor prognosis germ cell tumor treated with early high-dose chemotherapy with hematopoietic progenitor cell support: a single-center experience 40
Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger 40
Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma 40
Global approach to hepatic metastases from colorectal cancer: indication and outcome of intra-arterial chemotherapy and other hepatic-directed treatments 39
Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies 39
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer 39
Multiple cycles of PBPC-supported high-dose carboplatin and paclitaxel following mobilization with epirubicin and cisplatin are feasible but ineffective in treating patients with advanced non-small cell lung cancer 38
Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators 38
Real-world experience and clinical impact of drug-drug interactions in HR+/HER2- advanced breast cancer patients treated with abemaciclib plus endocrine therapy: the AB-ITALY study 37
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone 37
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 37
Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer 37
Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999 37
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination 36
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 36
Cell-free DNA as a diagnostic marker for cancer: current insights 36
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 36
Role of DNA repair machinery and p53 in the testicular germ cell cancer: A review 35
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 34
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer 34
Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study 34
Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: Results of an Italian multicentre study 34
Germ cell tumours of the testis 34
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 34
High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer 33
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy 33
Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor? 32
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma 32
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/ HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial 32
High-dose chemotherapy for adult-type ovarian granulosa cell tumors: a retrospective study of the European Society for Blood and Marrow Transplantation 31
Consider quality of life to improve quality of cancer guidelines 31
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 31
Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study 31
PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis 31
Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone 30
Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors 30
Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer 30
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 30
Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. 30
Hydroxychloroquine as Prophylaxis for COVID-19: A Review 29
Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience 29
First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party 29
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? 28
First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study 28
The prognostic value of pain in castration-sensitive prostate cancer 27
Clinical impact of pancreatic metastases from renal cell carcinoma: A multicenter retrospective analysis 27
Immunotherapy for prostate cancer: Where we are headed 26
Early use of abiraterone and radium-223 in metastatic prostate cancer 26
Circulating tumor cells in metastatic inflammatory breast cancer 25
Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide 25
Dose intensification in hormone receptor–negative and/or human epidermal growth factor receptor 2–negative high-risk primary breast cancer. 25
Sexual functions after high-dose chemotherapy in survivors of germ cell tumors 25
Circulating tumor cells in newly diagnosed inflammatory breast cancer 24
Totale 4.444
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.157
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.157
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20252.898 0 0 0 0 0 0 315 6 1.345 704 213 315
2025/20263.259 635 795 274 197 129 126 353 188 251 311 0 0
Totale 6.157